- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07469891
Une étude de phase 1 du PRT12396 chez des participants atteints de néoplasmes myéloprolifératifs sélectionnés
Étude de phase 1, en ouvert, multicentrique, évaluant la sécurité et l'efficacité du PRT12396 chez les participants atteints de polyglobulie de Vaquez et de myélofibrose
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.
The study is conducted in two parts:
Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).
Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.
Approximately up to 100 participants are planned for enrollment across both parts of the study.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Contact (Please Do Not Disclose Personal Information)
- Numéro de téléphone: See Email
- E-mail: clinicaltrials@preludetx.com
Lieux d'étude
-
-
South Australia
-
Adelaide, South Australia, Australie, 5000
- Recrutement
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australie, 3168
- Recrutement
- Monash Health, Monash Medical Centre
-
-
Western Australia
-
Nedlands, Western Australia, Australie, 6009
- Recrutement
- One Clinical Research
-
-
-
-
-
Barcelona, Espagne, 08036
- Recrutement
- Hospital Clinic de Barcelona
-
Madrid, Espagne, 28034
- Recrutement
- Hospital Universitario Ramon y Cajal
-
Madrid, Espagne, 28041
- Recrutement
- Hospital Universitario 12 de Octubre
-
Valencia, Espagne, 46010
- Recrutement
- Hospital Clínico Universitario de Valencia
-
-
-
-
-
Nice, France, 06200
- Recrutement
- Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
-
Paris, France, 75010
- Recrutement
- Saint-Louis Hospital
-
Toulouse, France, 31059
- Recrutement
- Oncopole Claudius Regaud
-
-
-
-
-
Florence, Italie, 50134
- Recrutement
- Azienda Ospedaliero Universitaria Careggi
-
-
-
-
California
-
Los Angeles, California, États-Unis, 90095
- Recrutement
- UCLA Ronald Reagan Medical Center
-
Sacramento, California, États-Unis, 95817
- Recrutement
- University of California, Davis Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, États-Unis, 80218
- Recrutement
- Colorado Blood Cancer Institute
-
-
Florida
-
Coral Springs, Florida, États-Unis, 33065
- Recrutement
- BRCR Global - Coral Springs
-
Miami, Florida, États-Unis, 33136
- Recrutement
- Sylvester Comprehensive Cancer Center
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- Moffitt Cancer Center
-
-
Michigan
-
Grand Rapids, Michigan, États-Unis, 49546
- Recrutement
- START Midwest, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Recrutement
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Tristar BMT
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Tennessee Oncology, PLLC - Investigational Drug Services
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- The University of Texas, MD Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
- Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
- Documented presence of a JAK2 V617 mutation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Estimate life expectancy of ≥12 weeks per investigator assessment.
- Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
- Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)
Exclusion Criteria:
- History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
- Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
- Active or uncontrolled infection requiring systemic therapy or hospitalization.
- Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
- Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
- Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
- Pregnancy or breastfeeding
- Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
- Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
- Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
- Participation in another interventional clinical study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: PRT12396: MF
Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
|
Expérimental: PRT12396: PV
Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Dose limiting toxicity (DLT) of PRT12396
Délai: Through cycle 1 (4 weeks)
|
Incidence of dose limiting toxicities, defined according to protocol-specified criteria |
Through cycle 1 (4 weeks)
|
|
Incidence and severity of Adverse events
Délai: Through study completion, an average of 2 years
|
Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0 |
Through study completion, an average of 2 years
|
|
Adverse Events Leading to Dose Modifications or Discontinuation
Délai: Through study completion, an average of 2 years
|
Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities |
Through study completion, an average of 2 years
|
|
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
Délai: Through study completion, an average of 2 years
|
Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data |
Through study completion, an average of 2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Hematologic Response Rate (PV)
Délai: Through study completion, an average of 2 years
|
Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator |
Through study completion, an average of 2 years
|
|
Duration of Hematologic Response (PV)
Délai: Through study completion, an average of 2 years
|
Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first |
Through study completion, an average of 2 years
|
|
Hematocrit Control Without Phlebotomy Requirements (PV)
Délai: Through study completion, an average of 2 years
|
Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy |
Through study completion, an average of 2 years
|
|
Spleen Response (MF)
Délai: Through study completion, an average of 2 years
|
Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length |
Through study completion, an average of 2 years
|
|
Change from Baseline in Hemoglobin (MF)
Délai: Through study completion, an average of 2 years
|
Change from baseline in hemoglobin levels in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Platelet Count (MF)
Délai: Through study completion, an average of 2 years
|
Change from baseline in platelet count in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Absolute Neutrophil Count (MF)
Délai: Through study completion, an average of 2 years
|
Change from baseline in absolute neutrophil count in MF participants |
Through study completion, an average of 2 years
|
|
Transfusion Independence (MF)
Délai: Through study completion, an average of 2 years
|
Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria |
Through study completion, an average of 2 years
|
|
Maximum Observed Plasma Concentration (Cmax)
Délai: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Maximum observed plasma concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Time To Maximum Concentration (Tmax)
Délai: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Time to maximum concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Area under the plasma concentration versus time curve (AUC)
Délai: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Area under the plasma concentration-time curve will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Terminal Elimination Half-life (T1/2)
Délai: Cycle 1 Day 1
|
Terminal elimination half-life will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Steady State Trough Concentrations
Délai: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Steady state trough concentrations will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Clearance
Délai: Cycle 1 Day 1
|
Clearance will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Accumulation
Délai: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Accumulation will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Délai: Through study completion, an average of 2 years
|
Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity. |
Through study completion, an average of 2 years
|
|
Patient Global Impression of Change (PGI-C)
Délai: Through study completion, an average of 2 years
|
Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms. |
Through study completion, an average of 2 years
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PRT12396-01
- 2026-525484-40-00 (Ctis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .